The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study
CONCLUSION: The combination of anlotinib and EC-T chemotherapy demonstrated tolerable side effects in the neoadjuvant treatment of early TNBC. pCR was higher than what has been reported in previous clinical studies of chemotherapy alone. This study provides additional rationale for using anlotinib plus docetaxel-epirubicin-based chemotherapy regimen in patients with early-stage TNBCs.PMID:38670862 | DOI:10.1016/j.clbc.2024.01.018 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Xi Chen Xinyu Wei Peizhuo Yao Yanbin Liu Haitao Guan Huafeng Kang Di Liu Yan Diao Xiaobin Ma Weili Min Changyou Shan Yang Zhao Fang Zhao Yuanyuan Chen Dong Xiao Qing She Youhuai Liu Yinbin Zhang Shuqun Zhang Source Type: research
Mitochondrial calcium uniporter as biomarker and therapeutic target for breast cancer: Prognostication, immune microenvironment, epigenetic regulation and precision medicine
CONCLUSION: MCU shows significant implication in prognosis, outcome prediction, microenvironmental shaping and precision medicine for BC. miR-29a-mediated MCU inhibition exerts therapeutic effect in tumor growth and metastasis.PMID:38663838 | DOI:10.1016/j.jare.2024.04.015 (Source: Cell Research)
Source: Cell Research - April 25, 2024 Category: Cytology Authors: Hung-Yu Lin Pei-Yi Chu Source Type: research
Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery : A Retrospective Cohort Study
CONCLUSIONS: Tumor response after the first course of NAC-DCF may be a good predictor of survival in patients with EC who underwent NAC-DCF plus surgery.PMID:38664331 | DOI:10.1245/s10434-024-15314-9 (Source: Ann Oncol)
Source: Ann Oncol - April 25, 2024 Category: Cancer & Oncology Authors: Takaomi Hagi Osamu Shiraishi Tomoya Nakanishi Masashi Kohda Yoko Hiraki Hiroaki Kato Atsushi Yasuda Masayuki Shinkai Motohiro Imano Takushi Yasuda Source Type: research
Alginate/carboxymethyl chitosan core-shell microspheres co-loaded with docetaxel/doxorubicin reverse chemotherapy resistance in anaplastic thyroid carcinoma
CONCLUSION: A-DOX@C-DTX microspheres exhibited superior anti-tumor effects compared to free drug treatment both in vitro and in vivo, particularly against drug-resistant ATC cells. This improved therapeutic efficacy may be attributed to the enhanced drug uptake and reduced drug efflux in drug-resistant ATC cells facilitated by ALG/CMC microspheres.PMID:38661518 | DOI:10.1089/thy.2024.0023 (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - April 25, 2024 Category: Endocrinology Authors: Yili Zhou Fan Yang Hongzhong Zhou Shixu Lv Source Type: research
An endothelial-related prognostic index for bladder cancer patients
ConclusionWe have effectively discerned pivotal genes from the endothelial cell perspective and constructed an EPI for BC patients, thereby offering promising prospects for precision medicine. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 25, 2024 Category: Cancer & Oncology Source Type: research
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer
R-loops are prevalent three-stranded nucleic acid structures, comprising a DNA-RNA hybrid and a displaced single-stranded DNA, that frequently form during transcription and may be attributed to genomic stabili... (Source: Molecular Cancer)
Source: Molecular Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Yufan Ying, Yuqing Wu, Fenghao Zhang, Yijie Tang, Jiahe Yi, Xueyou Ma, Jiangfeng Li, Danni Chen, Xiao Wang, Xiaoyan Liu, Ben Liu, Jindan Luo, Xiangyi Zheng and Liping Xie Tags: Research Source Type: research
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
In this study, we found that SPOP and ELK3 are an interacting partner. The interaction between SPOP and ELK3 resulted in increased ELK3 ubiquitination and destruction, assisted by checkpoint kinase-mediated ELK3 phosphorylation. Notably, the modulation of SPOP-mediated ELK3 protein stability affected the c-Fos-induced cell proliferation and invasion of PCa cells. The clinical involvement of the SPOP-ELK3 axis in PCa development was confirmed by an immunohistochemical assay on 123 PCa tissues, with an inverse correlation between increased ELK3 and decreased SPOP being present in ~80% of the specimens. This observation was s...
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Cheol-Jung Lee Heejung Lee Seo Ree Kim Soo-Bin Nam Ga-Eun Lee Kyeong Eun Yang Guk Jin Lee Sang Hoon Chun Han Chang Kang Joo Young Lee Hye Suk Lee Sung-Jun Cho Yong-Yeon Cho Source Type: research
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
Cell Death & Disease, Published online: 17 April 2024; doi:10.1038/s41419-024-06647-0ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance (Source: Cell death and disease)
Source: Cell death and disease - April 17, 2024 Category: Internal Medicine Authors: Cheol-Jung Lee Heejung Lee Seo Ree Kim Soo-Bin Nam Ga-Eun Lee Kyeong Eun Yang Guk Jin Lee Sang Hoon Chun Han Chang Kang Joo Young Lee Hye Suk Lee Sung-Jun Cho Yong-Yeon Cho Source Type: research
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer
This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomat...
Source: Asian Journal of Andrology - April 16, 2024 Category: Urology & Nephrology Authors: Shan-Shan Wang Xiao-Jie Bian Jun-Long Wu Bei-He Wang Sheng Zhang Ding-Wei Ye Source Type: research
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer
This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomat...
Source: Asian Journal of Andrology - April 16, 2024 Category: Urology & Nephrology Authors: Shan-Shan Wang Xiao-Jie Bian Jun-Long Wu Bei-He Wang Sheng Zhang Ding-Wei Ye Source Type: research
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer
This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomat...
Source: Asian Journal of Andrology - April 16, 2024 Category: Urology & Nephrology Authors: Shan-Shan Wang Xiao-Jie Bian Jun-Long Wu Bei-He Wang Sheng Zhang Ding-Wei Ye Source Type: research
Evaluating the docetaxel effect in an animal model of polyarthritis
ConclusionDTX reduces the progression and joint destruction in rats induced by Complete Freund ’s Adjuvant which may due to inhibition of PAD4, TNF-α, IL-1β, VEGF, and ACPA. Also, methotrexate exhibited anti PAD4 effect. (Source: Inflammopharmacology)
Source: Inflammopharmacology - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-related LncRNAs scores predicts chemotherapeutic responses and prognosis in cervical cancer patients
ConclusionsAn eight-IRlncRs-based prediction model was identified that has the potential to be an important tool to predict chemotherapeutic responses and prognosis for CC patients. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 14, 2024 Category: Cancer & Oncology Source Type: research
Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
CONCLUSIONS: GSL efficiently protected BMSCs from damage caused by TPF and recovered hematopoiesis.PMID:38610025 | DOI:10.1186/s12906-024-04445-x (Source: Cancer Control)
Source: Cancer Control - April 12, 2024 Category: Cancer & Oncology Authors: Haohui Lin Manhon Chung Jingchun Sun Yi Yang Li Zhang Xiaohua Pan Minghui Wei Sa Cai Yu Pan Source Type: research
Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Gu érin for the treatment of upper tract carcinoma in situ
CONCLUSION: Endoluminal Gem/Doce and BCG have similar oncological outcomes and major adverse event rates in the treatment of UT-CIS. Further prospective evaluation is warranted.PMID:38609747 | DOI:10.1016/j.urolonc.2024.03.012 (Source: Urologic Oncology)
Source: Urologic Oncology - April 12, 2024 Category: Urology & Nephrology Authors: Ian M McElree Sarah L Mott Helen Y Hougen Vignesh T Packiam Michael A O'Donnell Ryan L Steinberg Source Type: research
